产品
编 号：F715443
分子式：C26H29N5O2
分子量：443.54
分子式：C26H29N5O2
分子量：443.54
产品类型
规格
价格
是否有货
结构图
CAS No: 2415643-79-5
产品详情
生物活性：
IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders.
体内研究：
IQZ23 (20 mg/kg, i.p.) treatment significantly reverses high fat and cholesterol diet (HFC)- induced body weight increases and accompanying clinical symptoms of obesity in mice but without indicative toxicity. IQZ23 exhibits moderate terminal elimination half-lives (rat 4.2±0.3 h) and Cmax (rat 37.1±7.0 ng/mL) following oral administration (rat 5 mg/kg). IQZ23 exhibits terminal elimination half-lives (rat 4.4±0.4 h) following intravenous administration (rat 2 mg/kg).
体外研究：
IQZ23 activates AMPK pathway by modulating ATP synthase activity.IQZ23 (0.3 and 1.0 μM) markedly decreases the protein level of adipogenic factors C/EBPα, PPARγ, and sterol regulatory element-binding protein 1c (SREBP-1c)) after 24 h treatment as well as the level of fatty acid synthesis related proteins fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), stearoyl-CoA desaturase 1 (SCD1) after 6 days of treatment in 3T3-L1 adipocytes.
IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders.
体内研究：
IQZ23 (20 mg/kg, i.p.) treatment significantly reverses high fat and cholesterol diet (HFC)- induced body weight increases and accompanying clinical symptoms of obesity in mice but without indicative toxicity. IQZ23 exhibits moderate terminal elimination half-lives (rat 4.2±0.3 h) and Cmax (rat 37.1±7.0 ng/mL) following oral administration (rat 5 mg/kg). IQZ23 exhibits terminal elimination half-lives (rat 4.4±0.4 h) following intravenous administration (rat 2 mg/kg).
体外研究：
IQZ23 activates AMPK pathway by modulating ATP synthase activity.IQZ23 (0.3 and 1.0 μM) markedly decreases the protein level of adipogenic factors C/EBPα, PPARγ, and sterol regulatory element-binding protein 1c (SREBP-1c)) after 24 h treatment as well as the level of fatty acid synthesis related proteins fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), stearoyl-CoA desaturase 1 (SCD1) after 6 days of treatment in 3T3-L1 adipocytes.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备